X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Middle East and South Asia

Peli BioThermal Announces Acquisition of NanoCool

Content Team by Content Team
17th March 2020
in Middle East and South Asia, News
Vineti and Cryoport

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Peli BioThermal, the global name in temperature-controlled packaging, today announces the acquisition of NanoCool, an Albuquerque, New Mexico-based manufacturer of temperature-controlled packaging solutions. This acquisition further increases the breadth of the Peli BioThermal product portfolio, already the most comprehensive in the industry.

The addition of NanoCool customers, market segments and product technologies will enable Peli BioThermal to expand its access to patients, laboratories and other last-mile players in the distribution of life sciences materials and collection of patient laboratory samples.

“The core competency of Peli BioThermal and NanoCool— innovative temperature-controlled packaging — is very much aligned, but there is little overlap between our market segments and product technologies,” said David Williams, President of Peli BioThermal.

“Adding NanoCool’s capabilities to our diverse product line will help fuel our efforts to expand our offerings and bring further innovation to growing sectors of the life sciences industry spanning the globe. We will continue to lead innovation in temperature-controlled packaging with the addition of NanoCool’s customer-focused engineering approach — a methodology that both organisations fully embrace.”

NanoCool’s innovative evaporative cooling systems are the most convenient cold chain shipping containers available. With no need to refrigerate or pre-condition, NanoCool packaging can be stored at normal temperatures. A simple push of a button, engages the cooling technology and quickly conditions a payload space for shipping biological patient samples and other life science materials.

These unique characteristics, and highly efficient volumetrics, make NanoCool ideal for markets including specialty couriers, diagnostic laboratories, clinical supply providers and gene and cell therapy organisations. The company also has a dry-ice friendly parcel shipper and a version of its cooling engine that patients can send in a shipping envelope from their homes. Combining companies opens the door for Peli BioThermal to establish new customer relationships and further address cold chain challenges in these burgeoning markets.

“I’m thrilled to see NanoCool become part of the Peli BioThermal family. The Peli BioThermal brand is well known around the world for its temperature-controlled technology and we’re excited that our products will gain access to their resources and best-in-class industry expertise,” said Doug Smith, founder of NanoCool.

“Since we primarily serve customers in the U.S., we look forward to leveraging Peli BioThermal’s extensive global network to bring our innovative technology to more areas of the world – especially to areas where temperature-control is crucial.”

Smith will remain a consultant to NanoCool, and the NanoCoolfacility in New Mexico will continue to manufacture its products. Plans are underway to increase production at the facility to meet expected new sales following the acquisition.

Previous Post

Singapore Airlines Cargo receives CEIV Pharma renewal

Next Post

Peli BioThermal Share Sustainability Solutions at CTS Europe

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Peli BioThermal Announces Acquisition of NanoCool

Peli BioThermal Share Sustainability Solutions at CTS Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In